Pancreatitis - Pipeline Review, H2 2020

September 2020 | 106 pages | ID: PE58F81C1F9EN
Global Markets Direct

Abstracts

Pancreatitis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2020, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.
Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 1, 17, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Pancreatitis - Overview
Pancreatitis - Therapeutics Development
Pancreatitis - Therapeutics Assessment
Pancreatitis - Companies Involved in Therapeutics Development
Pancreatitis - Drug Profiles
Pancreatitis - Dormant Projects
Pancreatitis - Discontinued Products
Pancreatitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Pancreatitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2020
Pancreatitis - Pipeline by Bessor Pharma LLC, H2 2020
Pancreatitis - Pipeline by BioNTech SE, H2 2020
Pancreatitis - Pipeline by CalciMedica Inc, H2 2020
Pancreatitis - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020
Pancreatitis - Pipeline by Cypralis Ltd, H2 2020
Pancreatitis - Pipeline by D&D Pharmatech Co Ltd, H2 2020
Pancreatitis - Dormant Projects, H2 2020
Pancreatitis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pancreatitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Angion Biomedica Corp
Bessor Pharma LLC
BioNTech SE
CalciMedica Inc
Centeer BioTherapeutics Ltd Co
Cypralis Ltd
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Evive Biotech
General Regeneratives Shanghai Ltd
GlaxoSmithKline Plc
GNT Pharma Co Ltd
Johnson & Johnson
Koligo Therapeutics Inc
Lamassu Pharma LLC
LipimetiX Development Inc
Mallinckrodt Plc
Path BioAnalytics Inc
PNB Vesper Life Science Pvt Ltd
SCM lifescience Co Ltd
Shenzhen HighTide Biopharmaceutical Ltd
Sun BioPharma Inc
Takeda Pharmaceutical Co Ltd